Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ViscoHb 1.5
- Development stage
- Unknown
- Lead developer
- Iromed
- Administration
- Ophthalmic
01
Overview
ViscoHb 1.5 is a CE-marked ophthalmic viscoelastic device (OVD) developed and marketed by Iromed Group S.r.l. for use during intraoperative ophthalmic procedures, such as cataract surgery. It is a viscous, elastic solution typically composed of sodium hyaluronate that is injected into the eye to maintain the depth of the anterior chamber and protect the corneal endothelium and other intraocular tissues from mechanical trauma during surgical maneuvers. By providing a stable surgical environment and facilitating the implantation of intraocular lenses, it helps minimize post-operative complications and improve surgical outcomes.
- Brand names
- ViscoHb 1.5ViscoHb1.5ViscoHb-1.5ViscoHb
- Other names
- Ophthalmic Viscoelastic DeviceOVD
Beyond the preview
Go deeper on ViscoHb 1.5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ViscoHb 1.5.